Lots of organisations are looking to cure cancer and hard-to-treat diseases like influenza. Many are taking an immunotherapy approach, using a specifically engineered mRNA molecule (or other nucleic acid like pDNA). In the body, the mRNA activates the immune system to either attack the tumour or produce sufficient antibodies to act as a prophylactic vaccine. To achieve this, you need to get a sufficient amount of the drug payload into the cells effectively but without causing the body unwanted side effects.
That’s what we do with our breakthrough silica nanoparticle, Nuvec®.
Nuvec® particles have a unique irregular surface structure that simply and effectively traps and protects the mRNA as it travels to the cells. Once inside the cell, it is released to deliver a localised immune response. Nuvec® is also a natural adjuvant so it attracts large numbers of antigen presenting cells to increase the level of immune response needed for the body to develop immunity from the target pathogen.
To date, companies have tended to use existing delivery systems such as lipid nanoparticles, but unlike Nuvec®, these were not designed for working with nucleic acids and although they can also produce good immune responses they can also induce release of systemic inflammatory cytokines, meaning the patient will feel unwell, plus they may cause liver toxicity.
Nuvec® thus gives you a much greater chance of ensuring an effective cancer or antiviral drug comes out of the clinic.
Our revenues come from licencing Nuvec® technology to the people developing these cancer treatments or antiviral vaccines. They’ve got the innovative drug and we’re helping them by delivering it. Only by combining their unique mRNA / pDNA with our breakthrough delivery system will the therapy be successful.
The stages in this process are typically:
If you’d like further information or have any queries, please contact us.